Nā inoa o ka lāʻau sanovask > He hoʻomaʻemaʻe a me ke pale aku

Kuhi ʻia nā mea hoʻohui o ka lapaʻau sanovask, hoʻololi ʻia e ka hopena ma ke kino, ka hoʻomākaukau no ka mea hoʻokahi a ʻoi paha mau mea like. Ke koho ʻana i nā unuhi, e noʻonoʻo wale ʻaʻole i kā lākou kumukūʻai, akā no ke aupuni o ka hana a me ka maikaʻi hoʻi o ka mea hana.

ʻO ka wehewehe ʻana i ka lāʻau lapaʻau
Ka papa inoa o nā mea kikoʻī a me nā kumukūʻai
Hoike Mai
Nā ʻōlelo kuhikuhi i ka hoʻohana ʻana

ʻO ka wehewehe ʻana i ka lāʻau lapaʻau

Sanovask - Nā NSAID. He ia anti-inflammatory, analgesic a me nā antipyretic hopena, a ke pale aku nei i ka platelet aggregation. Hoʻopili ka hana o ka hana me ka pale ʻana i ka hana COX - ka mea nui o ka hoʻoneʻe o ka metabolism o ka acid arachidonic, kahi mea he mea no ka prostaglandins, e hana nui ana i ka pathogenesis o ka mumū, ʻeha a me nā ʻomaʻeha. ʻO ka emi ʻana o nā haʻawina o ka prostaglandins (ʻoi aʻe ka E 1) i ka waena o ka thermoregulation alakaʻi i kahi kaohi o ke ana o ke kino ma muli o ka hoʻonuiʻana o ke kīʻaha koko o ka ʻili a nui ka momona. ʻO ka hopena analgesic e pili ana i ka hana waena a me peripheral. Hoʻēmi i ka hoʻohui, platelet adhesion a me ka thrombosis e ka pale ʻana i ke kāpili ʻana o ka thromboxane A 2 i nā platelets.

Hoʻemi i ka make a me ka hopena o ke kūkulu ʻana i ka infarction myocardial me ka angina paʻa. E mālama pono i ka pale mua ʻana o nā maʻi o ka ʻōnaehana cardiovascular a me ka pale ʻana i ka lua o ka infarction myocardial. I loko o kēlā me kēia lā he 6 g a i ʻole paha, ke pale aku i ka synthesis o prothrombin i loko o ka ate a hoʻonui i ka manawa prothrombin. Hoʻonui i ka hana fibrinolytic plasma a hōʻemi i ka hoʻoliʻoliʻana o nā huaʻala coagulation hilinaʻi o ka K (II, VII, IX, X). Hoʻonui i nā hoʻopiʻi hemorrhagic i ka wā o ka interventions ka hoʻonui ʻana i ka hopena o ke koko i ka wā o ka maʻi me nā anticoagulants. Hoʻokomo i ka excretion o ka uric acid (hoʻonāukiuki hou i kona reabsorption i loko o ka renal tubules), akā i nā kiʻekiʻe kiʻekiʻe. Hoʻokiʻoki i ka COX-1 i ka mucosa gastric e alakaʻi i ka pale ʻana o nā prostaglandins gastroprotective, hiki iā ia ke alakaʻi i ka ulceration o ka membrane mucous a me ke koko hoʻoneʻe ma hope.

E hoʻokuʻu i ke ʻano, ka pale a me ka hoʻonohonoho

Hoʻopili ʻia nā papa ʻaina me kahi membrane film enteric o keʻokeʻo a ʻokoʻa paha ke keʻokeʻo, puni, biconvex, ma ka ʻaoʻao ʻaukā - kahi uʻi o ke ʻano keʻokeʻo a i ʻole keʻokeʻo a me kahi aho o ka manamana.

1 kōpō
acetylsalicylic acid	50 mg

Nā mea kūʻai: ka mololā lactose - 31.5 mg, cellulose microcrystalline - 16,3 mg, silikone koloila colloidal - 1.7 mg, sodium carboxymethyl starch - 0,5 mg.

Ka hana Shell: copolymer o ka waikawa methacrylic a me ka ethyl acrylate 1: 1 - 3.35 mg, povidone K17 - 0.56 mg, talc - 0.75 mg, macrogol 4000 - 0.34 mg.

10 kamepiula - nā kīpaha palemona (3) - nā ʻeke pepa.
10 kamepiula - nā papaki blister (6) - nā ʻeke pepa.
10 kamepiula - nā ʻili uila (9) - nā ʻeke pepa.
30 kiʻi - nā kīʻaha polymer (1) - nā ʻeke pepa.
60 pcs. - nā kīʻaha polymer (1) - nā ʻeke pepa.

1 kōpō
acetylsalicylic acid	75 mg

Nā mea kūʻai: ka mololā lactose - 47.25 mg, cellulose microcrystalline - 24.4 mg, silikone koloila colloidal - 2.6 mg, sodium carboxymethyl starch - 0.75 mg.

Ka hana Shell: copolymer o ka waikawa methacrylic a me ka ethyl acrylate 1: 1 - 6.7 mg, povidone K17 - 1.12 mg, talc - 1.5 mg, macrogol 4000 - 0.68 mg.

1 kōpō
acetylsalicylic acid	100 mg

Nā mea kūʻai: ka mololā lactose - 63 mg, cellulose microcrystalline - 32,6 mg, colloidal silicon dioxide - 3.4 mg, sodium carboxymethyl starch - 1 mg.

Ka hana Shell: copolymer o ka waikawa methacrylic a me ka ethyl acrylate 1: 1 - 10.05 mg, povidone K17 - 1.68 mg, talc - 2.25 mg, macrogol 4000 - 1.02 mg.

Ka hana lāʻau lapaʻau

Nā NSAID. He ia anti-inflammatory, analgesic a me nā antipyretic hopena, a ke pale aku nei i ka platelet aggregation. Hoʻopili ka hana o ka hana me ka pale ʻana i ka hana COX - ka mea nui o ka hoʻoneʻe o ka metabolism o ka acid arachidonic, kahi mea he mea no ka prostaglandins, e hana nui ana i ka pathogenesis o ka mumū, ʻeha a me nā ʻomaʻeha. ʻO ka emi ʻana o nā haʻawina o ka prostaglandins (ʻoi aʻe ka E 1) i ka waena o ka thermoregulation alakaʻi i kahi kaohi o ke ana o ke kino ma muli o ka hoʻonuiʻana o ke kīʻaha koko o ka ʻili a nui ka momona. ʻO ka hopena analgesic e pili ana i ka hana waena a me peripheral. Hoʻēmi i ka hoʻohui, platelet adhesion a me ka thrombosis e ka pale ʻana i ke kāpili ʻana o ka thromboxane A 2 i nā platelets.

Lapaʻau lāʻau

Ke lawaiʻa ʻia, lawe koke ʻia ʻo ia mai ka wahi e hoʻopili mai i ka ʻāpana liʻiliʻi a me ka liʻiliʻi mai ka ʻōpū. ʻO ka heleʻana o ka meaʻai i loko o ka ʻōpū e loli nui i ka hoʻopili ʻana o ka waikawa acetylsalicylic.

Hoʻomili ʻia ia i ka puʻu e ka hydrolysis me ka hoʻokumu ʻana o ka waikele salicylic, i ukali ʻia e ka hui pū me ka glycine a i ʻole glucuronide. Ka loli ka ʻike ʻana o nā salicylates i loko o ke kaila koko.

Ma kahi o 80% o ka salicylic acid e hoʻopili ai i nā protein plasma. E komo maʻalahi i nā Salicylates i loko o nā kikoʻehā a me nā wai o ke kino, ʻo ia hoʻi i loko o nā cerebrospinal, peritoneal a me nā synovial fluids. Ma nā liʻiliʻi liʻiliʻi, loaʻa nā salicylates i loko o nā lolo lolo, nā mahele - i ka bile, ka palu, ka palu. E komo koke ia i loko o ka paepae placental, ma kahi liʻiliʻi liʻiliʻi i hoʻopili ʻia i loko o ka waiū umauma.

I nā pēpē hou, hiki i ka salicylates ke kāhea i ka bilirubin mai ka pilina me ka albumin a kōkua i ka hoʻolālā ʻana o ka bilirubin encephalopathy.

Hoʻoulu ʻia ka penetration i ka lua i ka ʻōpū ma ke ʻano o ka hyperemia a me ka edema a me nā wili i lalo o ka hanana proliferative.

Ke loaʻa ka acidosis, ʻo ka hapanui o ka salicylate e hoʻohuli i ka waikona non-ionized, e komo pono i loko o nā i nā ʻili, me nā komo i ka lolo.

Hoʻokuʻu ʻia ia ma ka hoʻihoʻi ikaika o nā kuhi o nā pūpū i loli ʻole (60%) a i loko o nā ʻano o nā metabolites. Hoʻokumu ka hana o ka salicylate i loli ʻole i ka pH o ka urine (me ka alkalization o ka urine, ionization o ka salicylates i hoʻonui, hoʻonui i kā lākou reabsorption, a hoʻonui nui ʻia ka excretion). Ka waonaʻo T 1/2 acetylsalicylic ma kahi o 15 mau minuke. T 1/2 salicylate ke lawe ʻia ʻana ma nā wai haʻahaʻa he 2-3 mau hola, me ka hoʻonui ʻana i nā dosis he hiki ke hoʻonui a hiki i nā hola 15-30. I nā poʻe hānau hou, ʻoi aku ka wikiwiki o ka salicylate ma mua o ka pākeke.

Hōʻikeʻike i nā lāʻau lapaʻau

ʻO ka reheatatism, ʻo ka rehe, rūmatoid arthritis, hopohopo a me ka alopiko myocarditis, ke ala no ka maʻi hopohopo a me ka maʻi ʻana, ka maʻi palupalu me ke ʻano hōʻeha o nā ʻano o nā ʻano (me ka neuralgia, myalgia, hōʻea o ke poʻo), ka pale ʻana i ka trombosis a me ka embolism, ka mua a me ka pale ʻana o ka meocardial infarction , ke pale aku nei i nā ulia cerebrovascular e like me ka ischemic type.

In the immunology clinical and allergology: in unti hoʻonui i nā wa no ka hooliolo ʻana i ka "aspirin" forensitization a me ka hoʻokumu ʻana o ka hoʻomanawanui mau i nā NSAID i nā maʻi me ka "aspirin" asthma a me ka "aspirin triad".

Nā helu ICD-10

Aia ka helu ICD-10	Hōʻike ʻano
I21	Acocococute huehue
I40	Myocarditis huehue
I63	Loaʻa i ka mare cerebral
I74	Embolism a me ka trombosis arterial
I82	Embolism a me ka thrombosis o nā veins ʻē aʻe
M05	Ka lāʻau Haʻi Seropositive Rheumatoid
M79.1	Myalgia
M79.2	ʻO ka neuralgia a me ka palupalu
R50	Hōʻā ke kino
R51	Laumapa
R52.0	ʻEha ākea
R52.2	Nā maʻi ʻē aʻe ʻē aʻe (paʻa)

Loaʻa ka hopena

Mai ka pūnaehana ʻana: ka hanu, ka lua, ka anorexia, ka ʻeha o ka epigastric, ka ʻōpū ʻana, ʻaʻole pinepine - ka loaʻa ʻana o nā palaleka erosive a me ka ulcerative, ka huhū mai ka ʻeha o ka gastrointestinal, hana hana kīnā ʻole.

Mai ka ʻaoʻao o ka ʻōnaehana loko waena: me ka hoʻohana lōʻihi, dizziness, ka ʻeha, ka hoʻihoʻi ʻana i ka ʻike maka, tinnitus, meningitis aseptic.

Mai ka ʻōnaehana hemopoietic: luhi - thrombocytopenia, anemia.

Mai ka papa hoʻonohonoho coagulation koko: jarang - hemorrhagic syndrome, lending i ka wā koko.

Mai ka pūnaehana urinary: jarang - hana ʻole i ka hana lōkela, me ka hoʻohana lōʻihi - ka maikaʻi ʻole o ka renal, syndrome o ka nephrotic.

He maʻi kūloko: ʻaʻole - palaka ka ili, ka edema Quincke, bronchospasm, "aspirin triad" (ka hui pū ʻana o ka palaka bronchial, polyposis ka hopena o ka ihu a me ka paranasal sinuses a me ka hemahema o ka acetylsalicylic acid a me nā lāʻau pyrazolone).

Nā mea ʻē aʻe: i kekahi mau hihia - Hōʻailona o Reye, me ka hoʻohana lōʻihi - hoʻonui i nā hōʻailona o ka puʻuwai naʻau ʻole.

ʻŌpū a me ka lactation

Contectedicated i ka I and III trimesters o ka hapai. I ka trimester II no ka hapai, hiki i ke komo ʻana kahi mea e like me ke kuhikuhi ʻana i ka nui.

Loaʻa ia i kahi hopena teratogenic: i ka wā i hoʻohana ʻia ma ka trimester mua, alakaʻi ia i ka hoʻomohala ʻana o ka palate o luna, i ka kolu o ka lāʻala ia e hoʻohiolo ai i ka hana hana (inhibition of prostaglandin synthesis), ka wā o ka pani o ka ductus arteriosus i loko o ka pūpū, pulmonary vascular hyperplasia a me hypertension ma ka pulmonary circulation.

Hoʻopili ka Acetylsalicylic acid i ka waiū umauma, kahi e hoʻonui ai i ka hiki o ke kahe koko i loko o kahi keiki ma muli o ke ʻano o ke kumu platelet, no laila ʻaʻole pono ka makuahine e hoʻohana i ka acetylsalicylic acid i ka wā lactation.

Nā ʻōlelo kikoʻī

Hoʻohana ʻia me ka mālama pono ʻana i nā maʻi me nā maʻi o ka ate a me nā pōpoki, me ka hoʻōho o bronchial, erosive a me ulcerative lesion a me ke kahe mai ka gastrointestinal tract i loko o ka anamnesis, me ka nui o ke koko a me ka lāʻau hoʻomohala wale nō, decompensated a me ke ake ʻole.

ʻO ka acetylsalicylic acid a ma nā liʻiliʻi liʻiliʻi e hōʻemi ana i ka hoʻonuiʻana o ka waikik uric mai ke kino, hiki iā ia ke hōʻeha i kahi maʻi gout i nā mea maʻi hiki. I ka wā o ka mālama lōʻihi a me / a i ʻole ka hoʻohana ʻana i ka acetylsalicylic acid i nā koina kiʻekiʻe, koi ʻia ka nānā ʻana i nā mea lapaʻau a nānā pinepine ʻia nā pae hemoglobin.

Hoʻohana ʻia ka hoʻohana ʻana i ka acetylsalicylic acid ma ke ʻano he anti-inflammatory i loko o kēlā me kēia lā o 5-8 g ma muli o ka nui o nā hopena kūpono mai ka gastrointestinal tract.

Ma mua o ka hōʻemi ʻana, e hōʻemi i ke koko i ka wā o ka hoʻomaʻamaʻa ʻana a ma ka wā postoperative, pono ʻoe e kāpae i ka lawe ʻana i ka salicylates no nā lā 5-7.

I ka wā lōʻihi, pono ia e hōʻike i kahi hōʻike koko ākea a me ka hoʻāʻo ʻana i ka toto occult fecal.

ʻO ka hoʻohana ʻana o ka acetylsalicylic acid i ka pediatrics i contraindicated, ʻoiai i ka hihia i kahi maʻi maʻi o nā keiki ma lalo o ke kumu o ka acetylsalicylic acid, ʻo ka hōʻeha o ka hoʻomohala ʻana i ka maʻi o Reye. Hoʻomaʻamaʻa i nā ʻōuli o Reye o ka maʻi me ka hoʻopuni lōʻihi, ka encephalopathy aʻai, a me ka nui i hoʻonui ʻia.

ʻAʻole lōʻihi ka lōʻihi o ka mālama ʻana (me ke kūkā ʻana i ke kauka) 7 mau lā i ka wā i kuhikuhi ʻia ai he analgesic a ʻoi aku i nā lā 3 mau lā he antipyretic.

I ka wā mālama, pono ka mea maʻi e pale i ka inu ʻona.

Hoʻohui nūhou

Me ka hana like o nā antacids e loaʻa ana i ka magnesium a / a i ʻole hydroxide alumini, e lohi a hoʻemi i ka komo ʻana o ka acetylsalicylic acid.

Me ka hoʻohana pinepine ʻana o nā palaka saluran kalsi, nā lāʻau lapaʻau e kaupalena ana i ka komo ʻana o ka calcium a hoʻonui i ka excretion o ka calcium mai ke kino, ʻo ka piʻi ʻana o ke kahe koko.

Me ka hana like me ka acetylsalicylic acid, e hoʻonui ai i ka hopena o ka heparin a me nā kūlohelohe anticoagulants, nā mālamalama hypoglycemic o ka sulfonylureas, insulin, methotrexate, phenytoin, hoʻōla a valproic.

Me ka hoʻohana pū ʻana me corticosteroids, piʻi i ka nui o ka hana ulcerogenic a me ka ʻike ʻana i ke koko gastrointestinal.

Me ka hoʻohana like ʻana, ua hoʻemi ʻia ka maikaʻi o ka diuretics (spironolactone, furosemide).

Me ka hoʻohana like ʻana o nā NSAID āpau, e hoʻonui aʻe i ka hōʻeha o ka hopena ʻaoʻao. Hiki i ka acetylsalicylic acid ke hōʻemi i nā plasma plasma o ka indomethacin, piroxicam.

Ke hoʻohana ʻia i ka manawa like me ke hoʻomākaukau gula, hiki i ka acetylsalicylic acid e hoʻonāukiuki i ka pōʻino o ka ate.

Me ka hoʻohana like ʻana, hoʻemi ka maikaʻi o nā mea uricosuric (e komo pū ana me probenecid, sulfinpyrazone, benzbromarone).

Me ka hana like o ka acetylsalicylic acid me ka sodium alendronate, hiki i ka hoʻomohalaʻana o ka esophagitis koʻikoʻi.

Me ka hoʻohana like ʻana o griseofulvin, hiki i kahi hala ʻole o ka hoʻopili ʻana o ka acetylsalicylic acid.

Kahu i ka hihia o ka hemis iris spontan i ka wā e lawe ana i ka kiʻi o ginkgo biloba i ke ʻano o ka hoʻohana ʻana i ka acetylsalicylic acid i kahi maʻa o 325 mg / lā. Ua manaʻoʻiʻo ia paha kēia ma muli o ka hopena hoʻohui i ka hopena o ka platelet aggregation.

Me ka hoʻohana like o dipyridamole, hiki ke hoʻonui ʻia i ka C max o salicylate i loko o ke koko koko a me ka AUC.

Me ka hoʻohana like pū me ka acetylsalicylic acid, ka ʻike ʻana o ka digoxin, barbiturates a me nā paʻakai lithium ma ka hoʻonui ʻana i ke koko.

Me ka hana like o salicylates ma nā inika kiʻekiʻe me nā molika anhydrase carbonic, hiki nō ke komo i ka hoʻonaninani salicylate.

ʻO ka Acetylsalicylic acid ma nā emi ma lalo o 300 mg / lā i loaʻa kahi hopena mai ka hopena o ka captopril a me ka enalapril. Ke hoʻohana nei i ka acetylsalicylic acid i nā koina kiʻekiʻe, hiki ke hoʻemi i ka hopena o ka captopril a me ka enalapril.

Me ka hana like o ka caffeine hoʻonui i ka helu absorption, ka paila i ka plasma a me ka bioavailability o acetylsalicylic acid.

Me ka hoʻohana pinepine ʻana o ka metoprolol hiki ke hoʻonui i ka salicylate C max i loko o ke kaila koko.

Ke hoʻohana nei i ka pentazocine e pili ana i ka kāʻei o ka hoʻohana lōʻihi ʻana o ka acetylsalicylic acid i nā koina kiʻekiʻe, aia kahi pōʻino o nā hopena maikaʻi loa mai nā kau.

Me ka hoʻohana pinepine ʻana o ka phenylbutazone e hōʻemi ai i ka uricosuria i hoʻoili ʻia e ka acetylsalicylic acid.

Me ka hoʻohana like o ka ethanol hiki ke hoʻoikaika i ka hopena o ka acetylsalicylic acid ma ka digestive tract.

Nosological ʻano papa (ICD-10)

Nā Kiʻi Kūwili Koho	1 kōpō.
mea ikaika:
acetylsalicylic acid	50/75/100 mg
nā mea waiwai (inti): lactose monohilohi - 31.5 / 47.25 / 63 mg, MCC - 16.30 / 24.4 / 32.6 mg, colloidal silicon dioxide - 1.7 / 2.6 / 3.4 mg, sodium carboxymethyl starch - 0 5 / 0.75 / 1 mg
make a film he copolymer pākuʻi lāʻau methacrylic a me ethyl acrylate (1: 1) - 3.35 / 6.7 / 10.05 mg, povidone K17 - 0.56 / 1.12 / 1.68 mg, talc - 0.75 / 1.5 / 2.25 mg, macrogol 4000 - 0.34 / 0.68 / 1.02 mg

Lapaʻau lāʻau

ʻO ke ʻano o ka hana o ka acetylsalicylic acid (ASA) e kau ana i ka hoʻololi ʻole ʻana o ka COX-1, ma muli o ke ʻano o ka synthesis o PG, prostacyclins a me Tx i pāpā ʻia. Hoʻemi i ka hoʻohui, platelet adhesion, a me ka thrombosis e ka hoʻokae ʻana i ka synthole TxA2 i nā platelets. Hoʻonui ia i ka hana fibrinolytic o ke koko koko a hoʻēmi i ka paʻaʻana o nā huaʻala coagulation depend-bit K (II, VII, IX, X). ʻO ka hopena antiplatelet ka mea i hoʻolaha nui i nā platelets, no ka mea ʻaʻole hiki iā lākou ke hōʻi hou i ka COX. Hoʻomohala ka hopena antiplatelet ma hope o ka hoʻohana ʻia ʻana o nā pona liʻiliʻi o ka lālani a hoʻomau no 7 mau lā ma hope o hoʻokahi pae. ʻO kēia mau hiʻohiʻona o ka ASA e hoʻohana i ka pale a me ka mālama ʻana i ka infococote myocardial, maʻi maʻi coronary, nā ʻōmole o ka maʻi varicose. Aia kekahi ASA i ka hopena anti-inflammatory, analgesic, antipyretic.

Nā Hoʻohui

hypersensitivity i ka acetylsalicylic acid, nā mea waiwai i ka hoʻopili o ka lāʻau a me nā NSAIDs,

eroses a me nā ulcerative lesi o ka gastrointestinal tract (i ka ʻoi kumu),

Hoʻokomo ʻia ka bronthial asthma ma ka lawe ʻana i ka salicylates a me nā NSAIDs,

ka hui pū ʻana o ka pohō bronchial, the recurrent polyposis of the ihs and paranasal sinuses and intolerance to ASA,

hui pū me ka methotrexate ma ke ʻano o 15 mg / wiki a i ʻole.

pilikia hōʻeha loa (Cl creatinine ʻole ma mua o 30 ml / min),

nā koikoi maʻi nui (papa B a ma luna o ke kiʻekiʻe Child-Pugh),

ka maʻi paʻakikī āpau III - IV papa hana e like me ka papa NYHA,

ka lolika lactose, hemahema lactase, glucose / galactose malabsorption syndrome (ka wai i ka lactose monxidate),

hapai (I and III trimesters),

umauma umauma,

makahiki i 18 makahiki.

Me ka mālama: gout, hyperuricemia, gastric a me duodenal ulcer a i ʻole kahi moʻolelo o ke koko gastrointestinal (renal failed), renal failed (creatinine Cl ʻoi aku ma mua o 30 ml / min), mau pilikia ʻo CVD (e komo pū ana me ka puʻuwai puʻuwai, hypovolemia, ʻeha hoʻokō koʻikoʻi. wawao, sepsis a i nā hihia nui o ke kahe nui - ka hoʻoweliweli o ka hoʻomohala ʻana i ka pilikia a me ka hana ʻole ʻana o ka kidney ren), ke ole ʻana o ka ate (ma lalo o ka papa B ma ka pae keiki-Pugh), ʻākala bronchial, nā māhina palola paipai hanu, hay fever, nasal polyposis, lāʻau lapaʻau āpau, komo Nā NSAID, analgesics, anti-inflammatory, antirheumatic agents, grabe glucose-6-phosphate dehydrogenase deficiency (ASA hiki i ka hemolysis a me ka hemolytic anemia, nā mea hiki ke hoʻonui i ka hopena o ka hemolysis he hopena kiʻekiʻe o ka lāʻau lapaʻau, ʻeha a me nā maʻiʻeha) trimester), ka noiʻi ʻana i hoʻolele ʻia (e komo pū ai me nā mea liʻiliʻi, no ka laʻana, ka hoʻihoʻi ʻana i nā niho), ka hoʻomohala ʻana me ka methotrexate ma kahi haʻahaʻa e emi iho i ka 15 mg / pule, anticoagulants, thrombolytic a antiplatelet agents. a me ka mea, NSAIDs a me salicylicʻakika nā mea loaʻa i loko o nā māhele kiʻekiʻe, digoxin, hypoglycemic konohiki no ku una ana (sulfonylurea nā mea loaʻa) a me ka insulina, valproicʻakika, ka waiʻona (pakahi aku la ia kanakaʻona mau nā mea inu), SSRIs, ibuprofen (knm. "AaOIeIOUIeXAOAaIN").

Nā hopena hopena

Mai ka pūnaehana hana ʻana: pinepine - kaʻaʻi, puʻuwai, utuka, hōʻeha ma ka ʻōpū, kapa ʻole - ʻeha a me nā ʻōpū puʻupaʻa duodenal, ʻaʻole loa - nā maʻi pālua o ka ʻōpū a me ka duodenal mucosa, ka huhui o ka gastrointestinal, ka hopena o ka maʻi hepatic me ka hoʻonui ʻana o nā hana hepatic transaminases.

Mai ka ʻaoʻao o ka pīkī laha waena: hōʻeha, hoʻolohe lohi, tinnitus, ʻo ia paha kahi hōʻailona o kahi overdose o ka lāʻau (e nānā i ka "Overdose").

Mai ka ʻōnaehana hemopoietic: ka hoʻonui pinepine ʻana o ka maʻioperoper (intra- a me ka postoperative) ka maʻi, hematomas (bruises), nosebleeds, nā keʻa kahe, ke kahe mai ka genitourinary tract. Aia nā hōʻike no nā hihia koʻikoʻi o ka huhū, kahi e komo ai nā maʻi gastrointestinal a me ka hemorrhage cerebral (ʻoi aku hoʻi i nā poʻe maʻi me ka hypertension arterial i hiki ʻole i ka hopena koko pehu a / a i loaʻa i nā hanana concomitant me nā lāʻau anticoagulant), ma kekahi mau mea e hiki ke hoʻoweliweli. . ^ E Ha yM. Hiki ke alakaʻi i ka pīhoihoi i ka hoʻomohala ʻana i ke anemia ʻole a me ka uha posthemorrhagic / iron iron anemia (no ka laʻana, no ka hoʻokahe ʻoliala) me nā hōʻailona o nā klinika a me nā keʻena pono (asthenia, pallor, hypoperfusion). Aia nā hopena o nā hihia o ka hemolysis a me hemolytic anemia i nā mea maʻi me nā maʻi glucose-6-phosphate dehydrogenase.

Nā maʻi kūwaha: ka ʻāʻī o ka ʻili, kaʻeha, ka urticaria, ka edema o Quincke, rhinitis, ka huehue o ka membrane o ka mucal rongoa, bronchospasm, syndrome cardiorespiratory, a me nā hopena koʻikoʻi, e komo pū me ka anaphylactic shock.

Mai ka urinary system: aia nā mea pili i nā hihia o ka hana ʻole a me ka pani ʻole ʻana i kūleʻa.

Hoʻohui

Me ka hoʻohana like ʻana o ASA e hoʻonui i ka hopena o nā lāʻau lapaʻau i hōʻike ʻia ma lalo nei. Inā pono, ʻo ka hoʻokaʻawale ʻana o ASA me nā waihona i helu ʻia e noʻonoʻo pono i ka pono e hoʻemi i kā lākou dosis:

- methotrexate - ma muli o ka emi ʻana o ka hoʻomaʻemaʻe renal a me kāna neʻe ʻana mai ka kamaʻilio ʻana me nā protein,

- anticoagulants, thrombolytic a me antiplatelet agents (ticlopidine) - ke piʻi ka nui o ke koko ma muli o ka synergism o nā hopena therapeutic nui o nā lāʻau i hoʻohanaʻia.

- nā mea kanu me nā hopena anticoagulant, thrombolytic a i ʻole ka hopena antiplatelet, - he hoʻonui i ka hopena hoʻopōʻino i ka mucosa gastrointestinal,

- SSRI - hiki ke alakaʻi i ka nui o ka hoʻoheheʻe ʻana mai ka gastrointestinal tract kiʻekiʻe (synergism me ASA),

- digoxin - ma muli o ka emi ʻana o kona kūwaho renal, hiki iā ia ke alakaʻi i kahi overdose,

- nā haʻi hypoglycemic no ka hoʻokūkū waha (sulfonylurea derivatives) a me ka insulin ma muli o nā waiwai hypoglycemic o ASA pono i nā haʻahaʻa kiʻekiʻe a me ka neʻe mai o nā derogative sulfonylurea mai ka pilina me nā protein plasma koko,

- ka momona valproic - ke ulu nei kona mau maʻi ma muli o ka hoʻoili ʻia ʻana mai ka kamaʻilio ʻana me nā protein plasma koko,

- NSAID a me derivatives waikawa salicylic i nā koina kiʻekiʻe - nui ka hoʻonui ʻia o ka hopena ulcerogenic a me ke kahe ʻana mai ka huehue ʻana a hopena o ka synergism o ka hana,

- ibuprofen - aia ka antagonism e pili ana i ka hiki ʻole ke hoʻololi hou ʻia ʻana o ka thromboxanesynthetase ma muli o ke ʻano o ka hana ʻana o ASA, i ka hopena o ka hopena o nā hopena cardioprotective o ASA.

- eʻokiʻoki - i hoʻonui i ka pilikia o ka hanu o ka gastrointestinal a me ka hoʻolōʻihi i ka manawa o ke koko i ka hopena o ka hoʻonui ʻana i nā hopena o ka ASA a me ka ethanol.

ʻO ka mākaʻikaʻi o ka ASA i nā hala kiʻekiʻe e hiki ke hoʻonāukiuki i ka hopena o nā lāʻau lapaʻau i hōʻike ʻia ma lalo nei. Inā pono, ʻo ka koho manawa like ʻole o ka ASA me nā kālā i papa inoa ʻia e pono e noʻonoʻo i ka pono o ka hoʻoponopono hoʻoponopono kō:

- kekahi diuretics - ke emi nei ka hōʻemi i ka GFR ma muli o ka hoʻohaʻahaʻa ʻana i ka hoʻopili ʻana o nā GHG i nā ʻōpū,

- Hoʻolaha ka ACE - aia ka hōʻemi o ka hopena o ke kaukaʻi ʻana i ka GFR ma muli o ke kaohi ʻana o nā GHG me ka hopena vasodilating, kēlā, kahi nāwaliwali o ka hopena hypotensive. Hoʻomaʻamaʻa ʻia kahi hōʻemi haʻahaʻa i GFR me kahi laʻana o ASA i kēlā me kēia lā ma mua o 160 mg. Eia kekahi, aia ka emi ʻana o ka hopena cardioprotective maikaʻi o nā inhibitions ACE i ʻōlelo ʻia i nā mea maʻi no ka mālama ʻana i ka hōʻeha o ka naʻau. Hōʻike ʻia kēia hopena i ka wā e hoʻohana pū ai me ka ASA i loko o nā pupu he nui,

- nā lāʻau me ka hana uricosuric (benzbromaron, probenecid) - kahi hoʻohaʻahaʻa i ka hopena uricosuric ma muli o ka hoʻokūkū hoʻokūkū o ka renal tubular urinary acid excretion,

- nā corticosteroids systemic (me ka ʻike ʻole o ka hydrocortisone i hoʻohana ʻia no ka hoʻomaʻamau ʻana o ka maʻi o Addison) - loaʻa ka hoʻonui ʻana o ka paʻakū a me ka mea, me ka nāwaliwali o kā lākou hana.

ʻLoe a me ke kākele

I loko me ka hūnā ʻole, inu ʻana i nā ʻano wai he nui, ʻoi aku ma mua o ka papa ʻaina. Lawe ʻia nā papa he 1 manawa i ka lā.

Hoʻoholo ʻia ka lōʻihi o ka hopena e ke kauka hele mai.

ʻO ka pale mua a ka lāʻau myocardial infarction ma mua o nā mea pōpilikia. 50-100 mg / lā.

Hōʻalo ʻia ka infarent myocardial infarction, unstable and stabil angina pectoris. 50-100 mg / lā.

Angina paʻa ʻole (me ka hoʻomohala hoʻomohala ʻana i ka ʻaina myocardial infarction). ʻO ka paona mua o 100 mg (pono e hoʻokaʻawale ʻia ka papa ʻaina mua no ka hoʻihoʻi wikiwiki ʻana) pono e ka mea maʻi i ka wā hiki loa ma hope ke kānalua o ka hoʻomohala ʻana i ka hanana myocardial infarction. I nā lā 30 aʻe e hala ma hope o ka hoʻomohala ʻana o ka infarction myocardial, pono e mālama ʻia kahi nui o 200-300 mg / lā. Ma hope o 30 mau lā, pono ke kau ʻia ʻana o ka lāʻau kūpono e pale i ka hoʻēmi ʻana i nā myocardial infarction.

ʻO ka pale ʻana i ka ulia pōpilikia a me ka ulia cerebrovascular ulia. 75-100 mg / lā.

ʻO ka paleʻana i ka thromboembolism ma hope o ka hoʻomaʻemaʻe a me ka interventive vascular invasive. 50-100 mg / lā.

Ke kāohiʻana o ka DVT a me ka embolism pulmonary a me kāna mau lālā. 100-200 mg / lā.

Nā palapala ʻano:

hoʻohui papa pani

Aia i loko o hoʻokahi papa:

acetylsalicylic acid - 50.00 mg, 75.00 mg a i ʻole 100.00 mg.

Nā mea hoʻohanohano (core):

mololea lactose - 31.50 mg, 47.25 mg a i ʻole 63.00 mg, cellulose microcrystalline - 16.30 mg, 24.40 mg a 3260 mg, colloidal silicon dioxide - 1.70 mg, 2.60 mg a i ʻole 3.40 mg; sodium carboxymethyl starch 0.50 mg, 0.75 mg ai 1.00 mg.

Nā mea hana (shell):

copolymer o ka waikawa methacrylic a me ka ethyl acrylate 1: 1 - 3.35 mg, 6.70 mg a i ʻole 10.05 mg, povidone K17 - 0.56 mg, 1.12 mg a i 1.68 mg, talc - 0.75 mg, 1 , 50 mg a i ʻole 2.25 mg, macrogol 4000 - 0.34 mg, 0.68 mg aiʻole 1.02 mg.

ʻO ka papa papaʻu, biconvex, ke kiʻi ʻoniʻoni enteric, keʻokeʻo a ʻehu paha. Ma kahi ʻāpana ʻāpana: he keʻokeʻo a kokoke i keʻokeʻo paha ke kumu a me kahi manamana kiko.

Ke keu

Hiki i nā hopena koʻikoʻi, keu loa i nā mea maʻi a me nā keiki.

Hoʻokomo ka sindic Salicylism i ka wā e lawe ana i ka ASA ma kahi o kahi hapa o ka 100 mg / kg / lā no ka lā aku ma mua o 2 mau lā ma muli o ka hoʻohana ʻana o nā ʻano waiʻawaʻi o ka lāʻau ma ke ʻano he kumu lapaʻau kūpono (ʻaloʻole) a i ʻole he kuhi hanana hewa ʻole paha i kahi hanana waiʻaka o ka lāʻai i ka pākeke a i ʻole ke keiki. . ^ E Ha yM.

Kūpono i ka hōʻeha paʻakikī (hoʻokahi momona ma lalo o 150 mg / kg)

Nā Hoʻomaka hōʻeha, tinnitus, hoʻolohe lohi, hoʻonui ʻia, ke kuʻi a me ka luaʻi, ke kuʻuna, ka hilahila, tachypnea, hyperventilation, respiratory alkalosis.

Lāʻau: gastage lavage, hoʻomau hou ʻia o ka carbon activated, hoʻoneʻe alkaline diuresis, hoʻihoʻi hou o ka hoʻākāka wai-electrolyte a me KShchS.

Ka palena paʻakikī a me ke koʻikoʻi (hoʻokahi awhi o 150-300 mg / kg - hōʻeha haʻahaʻa, ʻoi aku ma mua o 300 mg / kg - mea hōʻino ikaika)

Nā Hoʻomaka alkalosis respiratory me ka hoʻokaʻawale metabolic acidosis, hyperpyrexia, hyperventilation, non-cardiogenic pulmonary edema, humuhumu kaumaha, asphyxia, ma ka ʻāpana CCC - arrhythmias cardiac, hōʻailona hōʻailona i ka hoʻokahe o ke koko, ka hoʻoneʻe ʻana o ka hana cardiac, ma ka ʻāpana o ka pauna o ka wai-electrolyte - dehydration, hana i ʻole ka hana mai ka ololi a hiki i ka hoʻomohala ʻana i ka hana renal, hōʻike ʻia e ka hypokalemia, hypernatremia, hyponatremia, pākīpī i ka glucose o ka glucose - hyperglycemia, hypoglycemia (he nui i nā keiki), etoatsidoz, tinnitus, pepeiao kuli, gastrointestinal hemorrhage, hematological kāna hana - ma inhibition o platelet aggregation i ka coagulopathy, i ka palena manawa px, hypoprothrombinemia, neurological kāna hana -ʻawahia encephalopathy a me ka hoʻoluhi hewa wale o ka Central ko mākou hopohopo'ōnaehana (drowsiness, ka hilahila, coma, convulsions).

Lāʻau: hale hoʻokipa ākea i nā keʻena kūikawā no ka hana ulia pōpilikia - lavage gastric, hoʻomohala hou i ka uluna i hoʻolaʻa ʻia, hoʻolaʻa neʻe i ka alkaline, hemodialysis, hoʻihoʻi hou i ka pale o ka wai-electrolyte a me ke kūpaʻa acid-base, ke ʻano hōʻailona.

Mea hana

E ʻae ana ka mea hana hana / hoʻonohonoho i nā hoʻopiʻi mea kūʻai: OJSC Irbit Chemical Farm. 623856, Rusia, Sverdlovsk wahi, Irbit, st. Kirova, 172.

Tel./fax: (34355) 3-60-90.

Kūlana hōʻike: Sverdlovsk Region, Irbit, ul. Karl Marx, 124-a.

ʻO ka mana o ke kānāwai ma ka inoa o kāna palapala kau inoa hoʻopaʻa ʻia: OAO Aveksima. 125284, Lūkia, Moscow, Leningradsky prospek, 31A, p. 1.

Nā hōʻailona no ka hoʻohana ʻana

ʻO ka maʻi keʻala ma nā maʻi maʻi a me nā maʻi.

ʻEha ka maʻi ʻeha (o nā ʻano kumu): ka ʻeha (me nā mea e pili ana i ka hoʻokaʻawale ʻana i ka waiʻona), ka migraine, ka ʻūhā, neuralgia, lumbago, radicular radicular syndrome, myalgia, arthralgia, algodismenorea.

Me ka lāʻau antiplatelet (e piʻi a hiki i 300 mg / lā): ka maʻi puʻukui coronary, ka ʻike ʻana i nā nui me nā pilikia no ka maʻi puʻuwai coronary, ischemia myocardial painless, palupalu ka theina pectoris, myocardial infarction. ʻO ka hōʻeha ʻana i nā kāne, ka hōʻili o ka puʻuwai prosthetic (pale a me ka mālama ʻana i ka thromboembolism), ka ballonary angioplasty a me ke kau ʻana i ka stent (hoʻemi i ka hopena o ka re-stenosis a me ka mālama ʻana i ka stratification o ka lua o ka coronary artery), me ka atheros nā maʻi kīlaha o nā corerary artery (ʻo ka maʻi Kawasaki), aortoarteritis (maʻi ʻo Takayasu), nā puʻuwai hipipular mitral a me ka fibrillation atrial, prolaps valle mitral (pale ʻana i ka thromboembolism), embolism aburrent pulmonary, pulmonary infarction, thrombophlebitis akuhula.

ʻO ka rumi o ke ʻano, ke ʻano o ka lākau o ka lālani, pūpū o ka maʻi myocarditis, pericarditis, roreumatic no ka hoʻohana ʻana i kēia manawa ..

Pehea e hoʻohana ai: dosis a me ke ʻano o ka mālama ʻana

Lawe ʻia nā papa o ka lāʻau lapaʻau me ka maʻi waha, me ka febrile a me nā maʻi hōʻehaʻeha no nā pākeke - 0.5-1 g / lā (a hiki i 3 g), i hoʻokaʻawale ʻia i 3 mau pona. ʻAʻole pono nā lōʻihi o ka mālamaʻana i nā hebedoma 2.

E hoʻomaikaʻi i nā waiwai o ka rheological o ke koko - 0.15-0.25 g / lā no kekahi mau mahina.

Hoʻololi ʻia nā papa e pili ana i ka ASA i nā inapo ma luna o 325 mg (400-500 mg) i hoʻohana no ka hoʻohana ʻana i kahi lāʻau lapaʻau analgesic a anti-inflammatory, i nā dosis o 50-75-100-300-325 mg i nā pākeke, ʻo ia ka mea ma ka lāʻau antiplatelet.

Me ka infarction myocardial, me ka pale ʻana i ka lua ma nā mea maʻi ma hope o ka myocardial infarction, 40-325 mg hoʻokahi manawa i ka lā (ma mua o 160 mg). E like me ka mea e hoʻopili ai i ka hoʻohui platelet - 300-325 mg / lā no ka manawa lōʻihi.Me nā maʻi cerebrovascular ikaika i ka kāne, ka thromboembolism cerebral - 325 mg / lā me ka hoʻonui ikaika i ka nui o 1 g / lā, no ka pale ʻana i ka hoʻi hou ʻana - 125-300 mg / lā. No ka pale ʻana i ka thrombosis a i ʻole komo ʻana o ka short aortic, 325 mg kēlā me kēia hola 7 i kahi intranasal gastric tube, a laila 325 mg mau waha he 3 mau lā i ka lā (maʻamau i hui pū ʻia me dipyridamole, kahi i hoʻopau ʻia ma hope o hoʻokahi pule, e hoʻomau i ka hoʻomohala mau me ka lāʻau lapaʻau).

Me ka rheumatism ikaika i kuhikuhi ʻia (ʻaʻole i kuhikuhi ʻia i kēia manawa) i loko o kēlā me kēia lā o 5-8 g no nā pākeke a me 100-125 mg / kg no nā ʻōpio (15-18 mau makahiki), ʻo ka nui o ka hoʻohana ʻana he 4-5 mau lā i ka lā. Ma hope o 1-2 mau pule o ka mālama ʻana, hoʻemi ʻia nā keiki i ka dosis i 60-70 mg / kg / lā, hoʻomau ʻia ka mālama ʻana o nā pākeke i nā maʻi like, a hiki i ka 6 wiki ka lōʻihi o ka mālama ʻana. Hoʻololi ʻia ka hoʻopau ʻana ma o nā hebedoma 1-2.

Nā nīnau, nā pane, nā loiloi o ka lāʻau lapaʻau ʻo Sanovask

ʻO ka ʻikepili i hāʻawi ʻia e hana no nā lāʻau lapaʻau a me nā lāʻau lapaʻau. Aia nā ʻike e pili ana i ka lāʻau lapaʻau e pili ana i nā ʻōlelo i hoʻopili ʻia e ka mea hoʻopiʻi e ka mea hana. ʻAʻohe ʻikepili i hoʻopili ʻia ma kēia a ʻole kekahi ʻaoʻao o ka pūnaewele a mākou e hiki ke lawelawe ma kahi kūʻokoʻa no ka hoʻopiʻi pilikino i ka loea.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

Nā Papa - 1 papa:

Nā mea waiwai: acetylsalicylic acid 50 mg,
Nā mea hoʻihoʻi: ʻO nā mea hoʻihoʻi: ka nui o ka huaʻai o ka lactose - 31.5 mg, cellulose microcrystalline - 16,3 mg, silikone koloila colloidal - 1.7 mg, sodium carboxymethyl starch - 0,5 mg,
hana kiko: copolymer o ka waikawa methacrylic a me ka ethyl acrylate 1: 1 - 3.35 mg, povidone K17 - 0.56 mg, talc - 0.75 mg, macrogol 4000 - 0.34 mg.

30 papa i kēlā me kēia pā.

Nā NSAID. He ia anti-inflammatory, analgesic a me nā antipyretic hopena, a ke pale aku nei i ka platelet aggregation. Hoʻopili ka hana o ka hana me ka pale ʻana i ka hana COX - ka mea nui o ka hoʻoneʻe o ka metabolism o ka acid arachidonic, kahi mea he mea no ka prostaglandins, e hana nui ana i ka pathogenesis o ka mumū, ʻeha a me nā ʻomaʻeha. ʻO ka emi ʻana o nā kiko o ka prostaglandins (ma mua o E1) i ka waena o ka thermoregulation e alakaʻi i kahi kahe o ke ea o ke kino ma muli o ka hoʻonuiʻana o ke kīʻaha koko o ka ʻili a hoʻonui nui ʻia. ʻO ka hopena analgesic e pili ana i ka hana waena a me peripheral. Hoʻēmi i ka hoʻohui, plathes adhesion a me ka thrombosis e ka pale ʻana i ka hoʻopili ʻana i ka thromboxane A2 ma platelets.

I nā pēpē hou, hiki i ka salicylates ke kāhea i ka bilirubin mai ka pilina me ka albumin a kōkua i ka hoʻolālā ʻana o ka bilirubin encephalopathy.

Hoʻoulu ʻia ka penetration i ka lua i ka ʻōpū ma ke ʻano o ka hyperemia a me ka edema a me nā wili i lalo o ka hanana proliferative.

Ke loaʻa ka acidosis, ʻo ka hapanui o ka salicylate e hoʻohuli i ka waikona non-ionized, e komo pono i loko o nā i nā ʻili, me nā komo i ka lolo.

Hoʻokuʻu ʻia ia ma ka hoʻihoʻi ikaika o nā kuhi o nā pūpū i loli ʻole (60%) a i loko o nā ʻano o nā metabolites. Hoʻokumu ka hana o ka salicylate i loli ʻole i ka pH o ka urine (me ka alkalization o ka urine, ionization o ka salicylates i hoʻonui, hoʻonui i kā lākou reabsorption, a hoʻonui nui ʻia ka excretion). ʻO T1 / 2 o ka acetylsalicylic acid e like me 15 mau minuke. ʻO T1 / 2 o ka salicylate ke lawe ʻia ʻana ma nā wai haʻahaʻa he 2-3 mau hola, me ka hoʻonui ʻana i nā dosis he hiki ke hoʻonui a hiki i nā hola 15-30. I nā poʻe hānau hou, ʻoi aku ka wikiwiki o ka salicylate ma mua o ka pākeke.

Sanovask E hoʻohana i ka wā hāpai a me nā keiki

Contectedicated i ka I and III trimesters o ka hapai. I ka trimester II no ka hapai, hiki i ke komo ʻana kahi mea e like me ke kuhikuhi ʻana i ka nui.

Contraindication: nā makahiki o nā keiki (a hiki i 15 makahiki - ka hopena o ke ala o Reye syndrome i nā keiki me hyperthermia ma muli o nā maʻi maʻi.

Kākoʻo Sanovask

Kanakaiho. No ka poʻe pākeke, hoʻokahi ʻano maʻi hoʻokahi mai 40 mg a 1 g, i kēlā me kēia lā - mai 150 mg a 8 g, ka nui o ka hoʻohana - 2-6 mau manawa / lā.

Hoʻohana ʻia ka hoʻohana ʻana i ka acetylsalicylic acid ma ke ʻano he anti-inflammatory i loko o kēlā me kēia lā o 5-8 g ma muli o ka nui o nā hopena kūpono mai ka gastrointestinal tract.

Ma mua o ka hōʻemi ʻana, e hōʻemi i ke koko i ka wā o ka hoʻomaʻamaʻa ʻana a ma ka wā postoperative, pono ʻoe e kāpae i ka lawe ʻana i ka salicylates no nā lā 5-7.

I ka wā lōʻihi, pono ia e hōʻike i kahi hōʻike koko ākea a me ka hoʻāʻo ʻana i ka toto occult fecal.

ʻAʻole lōʻihi ka lōʻihi o ka mālama ʻana (me ke kūkā ʻana i ke kauka) 7 mau lā i ka wā i kuhikuhi ʻia ai he analgesic a ʻoi aku i nā lā 3 mau lā he antipyretic.

I ka wā mālama, pono ka mea maʻi e pale i ka inu ʻona.

ʻŌpū a me ka lactation

Kahawai

ʻO ka hoʻohana nui ʻana o nā salicylates nui i loko o ka 3 mau mahina o ka hāpai ʻana i pili me ka hoʻonui ʻana i ka nui o nā maʻi fetal (ka wehe ʻana o ka palate o luna, nā puʻuwai naʻau). ʻO ke koho ʻana o nā salicylates i ka mea mua o ka hānau ʻana o ka hapai, ua contraindicated.

I ka lua o ka hapalua o ka hapai ʻana, hiki ke kuhikuhi ʻia nā salicylates i ka noʻonoʻo ʻana i kahi loiloi koʻikoʻi o ka loaʻa ʻana o ka hōʻemi a me nā pono no ka makuahine a me ka ʻōpio, ʻoi aku ka maikaʻi i nā pākuʻi ʻaʻole iʻoi aku ma mua o 150 mg / lā a no ka manawa pōkole.

I ka trimester hope loa o ka hāpai ʻana, ka salicylates ma kahi kiʻekiʻe nui (ʻoi aku ma mua o 300 mg / lā) e hoʻokaʻawale i ka hana, hana mua i ka ductus arteriosus i ka pūpū, hoʻonui nui ʻia ka huhū ma ka makuahine a me ka maʻi fetus, a me ka hoʻokele ma mua o ka hānau ʻana e hōʻeha i ka hemorrhage intracranial, aemaise i nā pēpē ma mua. ʻO ke koho ʻana o salicylates i ka lā hope loa o ka hapai i contraindicated.

Hoʻohana i ka wā lactation

Salicylates a me kā lākou metabolites i loko o nā liʻiliʻi liʻiliʻi e hoʻokomo i ka waiū umauma. Hōʻalo ka hoʻolilo ʻana o ka salicylates i ka wā lactation me ka hoʻomohala ʻia ʻana o nā hopena maikaʻiʻole i ke keiki ʻaʻole pono me ka hoʻomaʻamaʻa ʻana o ka ʻōpiopio. Eia nō naʻe, me ka hoʻohana mau ʻana o ka lāʻau lapaʻau a i ʻole ke koho ʻana i kahi papa kiʻekiʻe, pono ke hoʻopau koke ka mālama ʻana i ka umauma.